Mirococept (APT070), an antibody designed to target the complement system components C3b/C4b and act as a membrane-localizing C3 convertase inhibitor, effectively diminishes the release of C-peptide and pro-inflammatory cytokines. It also curtails the infiltration of inflammatory cells and intraislet inflammation, offering advantages for islet transplantation. Furthermore, Mirococept mitigates increased vascular permeability in intestinal and pulmonary contexts, thereby reducing neutrophil influx [1] [2].